Scoop: As Sio closes, former CEO from ‘vant exit finds himself at helm of Irv Weissman stealth biotech
Stanford stem cell luminary Irv Weissman is building a new biotech around the ‘don’t eat me’ signal CD47 — but instead of cancer, the new biotech is developing anti-CD47 therapies for heart disease.
Bitterroot Bio, named after the Bitterroot river in Weissman’s home state of Montana, “likely will unveil our intentions early in 2023,” co-founder Nicholas Leeper told Endpoints News in an email, though he declined to say more. Bitterroot is going after “atherosclerosis from the anti-CD47 angle,” according to Weissman’s disclosures in a Nature Cancer paper published in November.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
